Menstrual cycle timing may change how exercise impacts blood sugar in type 1 diabetes

NCT ID NCT05188014

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This study looks at how different phases of the menstrual cycle affect blood glucose changes during exercise in women with type 1 diabetes who take oral contraceptives. Participants wear a continuous glucose monitor and complete a 45-minute aerobic exercise session during both the active pill phase and the placebo pill phase. The goal is to understand whether cycle timing influences blood sugar responses, which could help women with type 1 diabetes tailor their exercise routines.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could help women with type 1 diabetes better manage their blood sugar during exercise by accounting for menstrual cycle timing.
What could go wrong
This is a small, early-stage observational study with only 15 participants, so findings may not apply to all women with type 1 diabetes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2022

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * type 1 diabetes diagnosed for at least 1 year * regular menses * using monophasic oral contraceptives * residing in Edmonton, Alberta and able to visit the lab at the University of Alberta Exclusion Criteria: * HbA1c \> 9.9% * frequent and unpredictable hypoglycemia * change in insulin management strategy within two months of the study * use of an automated insulin delivery system * blood pressure \> 140/95 * history of cardiovascular disease * severe peripheral neuropathy * active proliferative retinopathy * use of medications (other than insulin) that would affect blood glucose levels * any musculoskeletal condition that would contraindicate exercise (e.g. sprain, strain, joint injury, etc.)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 1 diabetes are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Alberta Diabetes Institute

    RECRUITING

    Edmonton, Alberta, T6G 2R3, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.